Evidence map›Paper›PMID 37171706›Full record

ReviewJournal of nephrology2024

The rationale for intermittent administration of PTH in the management of mineral and bone disorder of chronic kidney disease.

Michael Pazianas, Paul D Miller

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of nephrology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Michael PazianasInstitute of Musculoskeletal Sciences, Oxford University, Oxford, OX3 7LD, UK. Michael.Pazianas@ndorms.ox.ac.uk.ORCID 0000-0002-4670-0016
Paul D MillerUniversity of Colorado Health Sciences Center, Denver, CO, 80262, USA.
University of Colorado Health · USUniversity of Oxford · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A major complication of chronic kidney disease is the derangement of mineral metabolism, leading to increased risk of fractures and cardiovascular mortality. Current therapeutic regimens are focused on reducing parathyroid hormone levels caused by secondary hyperparathyroidism, and the active vitamin D metabolite l,25(OH)

Indexed as

Fibroblast Growth Factor-23Parathyroid HormoneRenal Insufficiency, ChronicCalciumChronic Kidney Disease-Mineral and Bone DisorderDrug Administration ScheduleFibroblast Growth FactorsHumansHyperparathyroidism, SecondaryPhosphatesVitamin DCalciumFGF23 protein, humanFibroblast Growth Factor-23Fibroblast Growth FactorsParathyroid HormonePhosphatesVitamin D1,25(OH)2 vitamin D (Calcitriol)CalciumChronic kidney disease-mineral and bone disorder (CKD-MBD)Fibroblast growth factor 23 (FGF-23)Parathyroid hormone (PTH)Phosphate

Identifiers

PMID37171706
OpenAlexW4376225689

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.